China NMPA Drug Inspection - Jilin Daojun Pharmaceutical Co., Ltd. - Ibuprofen sustained-release capsules
China NMPA drug inspection for Jilin Daojun Pharmaceutical Co., Ltd. published May 15, 2020. Drug: Ibuprofen sustained-release capsules. On May 15, 2020, the Chongqing Municipal Drug Administration announced the findings of a quality supervision inspection
One-time purchase from the GKS catalog. Lifetime access in your library. Single documents and full company profiles available. All sales final.
China NMPA drug inspection for Jilin Daojun Pharmaceutical Co., Ltd. published May 15, 2020. Drug: Ibuprofen sustained-release capsules. On May 15, 2020, the Chongqing Municipal Drug Administration announced the findings of a quality supervision inspection
Access our comprehensive regulatory intelligence platform to analyze patterns, track compliance trends, and stay ahead of regulatory changes.
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox